Aciex Therapeutics competitors

Michael Cola joined Medgenics as President and CEO in September 2013. Prior to joining Medgenics, Mr. Cola served as President of Specialty Pharmaceuticals at Shire plc, a global specialty pharmaceutical company, from 2007 until April 2012. He joined Shire in 2005 as EVP of Global Therapeutic Business Units and Portfolio Management. Prior to joining Shire, he was with Safeguard Scientifics, Inc., a growth capital provider to life sciences and technology companies, where he served as President of the Life Sciences Group. While at Safeguard, Mr. Cola served as Chairman and CEO of Clarient, Inc., a cancer diagnostics company subsequently acquired by GE Healthcare, and as Chairman of Laureate Pharma, Inc., a full-service contract manufacturing organization serving research-based biologics companies. Prior to Safeguard Scientifics, Mr. Cola held senior positions in product development and commercialization at AstraMerck, a top 20 U.S. pharmaceutical company, and at AstraZeneca, a global biopharmaceutical company. Mr. Cola received a B.A. in biology and physics from Ursinus College and an M.S. in biomedical science from Drexel University. He serves on the Board of Directors of Vanda Pharmaceuticals Inc., Sage Therapeutics, Ben Franklin Technology Partners and Pennsylvania BIO, the statewide association representing the bioscience community. He also currently serves as Chairman of the Board of Governors of the Boys & Girls Clubs of Philadelphia.

Antony Mattessich joined Ocular as Chief Executive Officer in August of 2017. Prior to joining the company, he was Managing Director of Mundipharma International based in Cambridge, England. Previous to his time at Mundipharma, Antony ran the US respiratory, dermatology and pediatrics group at Novartis. He also held several positions at Bristol-Myers Squibb, among them, Managing Director roles in Malaysia/Singapore and The Netherlands, and Head of Operations for the International Medicines Group. Antony holds a BA from the University of California at Berkeley and a Masters in International Affairs from Columbia University.

Joshua M. Tarnoff is a CEO at JDP Therapeutics Inc.

Peter McWilliams is a Venture Partner at Sanderling Ventures, Chairman at CalciMedica Inc, and Chairman/Acting CEO at Axikin Pharmaceuticals and is based in San Francisco Bay Area. He has experience at Harkness Pharmaceuticals Inc and Oxford Molecular Group and has worked as Team Member at Cylene Pharmaceuticals, Managing Director at Sanderling Ventures, and Associate at Strategy&. Peter works or has worked as Associate at BOOZ ALLEN HAMILTON HOLDING CORP. He attended Princeton University, Columbia Business School, and University of Cambridge.